Table 4.
Distribution frequency of the clinical status and H19 rs2107425 genotype frequencies in 431 UCC patients.
| H19 (rs2107425) | ||||
|---|---|---|---|---|
| Variable | CC (%) (n = 152) | CT+TT (%) (n = 279) | OR (95% CI) | p Value |
| Stage | ||||
| Non muscle invasive tumor (pTa–pT1) | 94 (61.8%) | 141 (50.5%) | 1.000 (reference) | |
| Muscle invasive tumor (pT2–pT4) | 58 (38.2%) | 138 (49.5%) | 1.586 (1.06–2.373) | 0.025 |
| Tumor T status | ||||
| Ta | 37 (24.3%) | 53 (19%) | 1.000 (reference) | |
| T1–T4 | 115 (75.7%) | 226 (81%) | 1.372 (0.852–2.209) | 0.193 |
| Lymph node status | ||||
| N0 | 136 (89.5%) | 244 (87.5%) | 1.000 (reference) | |
| N1+N2 | 16 (10.5%) | 35 (12.5%) | 1.219 (0.651–2.284) | 0.536 |
| Metastasis | ||||
| M0 | 150 (98.7%) | 267 (95.7%) | 1.000 (reference) | |
| M1 | 2 (1.3%) | 12 (4.3%) | 3.371 (0.744–15.262) | 0.115 |
| Histopathologic grading | ||||
| Low grade | 16 (10.5%) | 37 (13.3%) | 1.000 (reference) | |
| High grade | 136 (89.5%) | 242 (86.7%) | 0.769 (0.413–1.435) | 0.410 |
Bold font indicates statistical significance (p < 0.05). The OR with their 95% CI were estimated by logistic regression models.